Bayer AG BAYN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BAYN is a good fit for your portfolio.
News
-
Bayer Reshapes Pharmaceutical Division Leadership to Fuel Growth
-
Bayer Menopause Drug Meets Key Goal in Late-Stage Trial
-
Bayer to Let Go Most Employees of Consultancy Unit
-
Bayer Wins Latest Philadelphia Trial Over Weedkiller Roundup
-
Bayer Decides Against Splitting Into Separate Units for Now — 2nd Update
-
Bayer Aims to Improve Credit Rating
-
Bayer Decides Against Splitting Up Company For Now — Update
-
Bayer Decides Against Splitting Up Company For Now
Trading Information
- Previous Close Price
- €26.18
- Day Range
- €25.88–26.06
- 52-Week Range
- €23.78–—
- Bid/Ask
- €26.06 / €26.08
- Market Cap
- €25.57 Bil
- Volume/Avg
- 1,400 / 4.7 Mil
Key Statistics
- Price/Earnings (Normalized)
- 4.11
- Price/Sales
- 0.54
- Dividend Yield (Trailing)
- 9.17%
- Dividend Yield (Forward)
- 9.17%
- Total Yield
- 9.17%
Company Profile
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and other consumer healthcare products. The firm also has a crop science business that includes seeds, pesticides, herbicides, and fungicides, which was expanded through the acquisition of Monsanto.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 99,723
- Website
- https://www.bayer.com
Competitors
Valuation
|
Metric
|
BAYN
|
BASFY
|
PFE
|
|---|---|---|---|
Price/Earnings (Normalized) | 4.11 | 20.47 | 13.80 |
Price/Book Value | 0.78 | 1.24 | 1.61 |
Price/Sales | 0.54 | 0.65 | 2.45 |
Price/Cash Flow | 3.36 | 7.97 | 13.18 |
Price/Earnings
BAYN
BASFY
PFE
Financial Strength
|
Metric
|
BAYN
|
BASFY
|
PFE
|
|---|---|---|---|
Quick Ratio | 0.79 | 1.06 | 0.58 |
Current Ratio | 1.27 | 1.98 | 0.91 |
Interest Coverage | −0.03 | 1.97 | 0.74 |
Quick Ratio
BAYN
BASFY
PFE
Profitability
|
Metric
|
BAYN
|
BASFY
|
PFE
|
|---|---|---|---|
Return on Assets (Normalized) | 5.19% | 3.00% | 4.98% |
Return on Equity (Normalized) | 17.17% | 6.46% | 10.90% |
Return on Invested Capital (Normalized) | 9.39% | 4.68% | 7.28% |
Return on Assets
BAYN
BASFY
PFE
Drug Manufacturers - General Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Xxcdtwycy | Kdlnj | $709.2 Bil | |
JNJ
| Johnson & Johnson | Nrhzqppkq | Wfrtc | $351.2 Bil | |
MRK
| Merck & Co Inc | Tvjnpldxd | Vpqg | $317.2 Bil | |
ABBV
| AbbVie Inc | Mglbysg | Srtt | $291.6 Bil | |
AZN
| AstraZeneca PLC ADR | Plcsrfzqpc | Qtrbf | $210.7 Bil | |
RHHBY
| Roche Holding AG ADR | Ccvgwtsf | Nhyn | $194.6 Bil | |
NVS
| Novartis AG ADR | Krkgrjhq | Xvkl | $189.7 Bil | |
PFE
| Pfizer Inc | Qgnclrnys | Jysv | $143.8 Bil | |
AMGN
| Amgen Inc | Dplfsdjwr | Rzp | $140.9 Bil | |
SNY
| Sanofi SA ADR | Slbcldpjq | Vdr | $113.5 Bil |